AKTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Akari Therapeutics PLC (AKTX) is not a strong buy at this time for a beginner investor with a long-term strategy. The technical indicators show bearish trends, and there are no significant positive catalysts or signals from Intellectia Proprietary Trading Signals. Additionally, the financial performance is weak, with no revenue growth and negative net income. While there is a 'Buy' rating from Ladenburg with a $1 price target, the lack of recent news, congressional trading data, and significant insider or hedge fund activity suggests limited momentum or confidence in the stock. Given the investor's impatience and long-term focus, it is better to hold off on investing in AKTX until stronger signals or catalysts emerge.
The technical indicators for AKTX are bearish. The MACD is above 0 but positively contracting, suggesting weakening momentum. The RSI is neutral at 43.387, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below the pivot level of 0.241, with key support at 0.224 and resistance at 0.259. Overall, the technical setup does not support a strong buy.
Ladenburg initiated coverage with a 'Buy' rating and a $1 price target.
No recent news, no significant insider or hedge fund trading activity, and weak financial performance with no revenue growth.
In Q3 2025, the company reported no revenue growth (0% YoY), a net income of -$6.4M (up 121.07% YoY but still negative), and no EPS growth. Gross margin remains at 0%. Overall, the financials indicate a struggling company.
Ladenburg initiated coverage on January 5, 2026, with a 'Buy' rating and a $1 price target. No other recent analyst updates are available.
